P162: Upadacitinib in Crohn’s Disease Patients: for what type of patients in real world setting ?ECCO'24Year: 2024
Authors: JuilleratMSc, P.(1,2,3)*;Martinho-Grueber , M.(1,2);Ruetsch, R.(2);Moubayed, H.(1);Vullièmoz-, M.(1);Michetti. , P.(1,4);
(1)Crohn and Colitis center- GEB La Source Beaulieu, Gastroenterology, Lausanne, Switzerland;(2)Gastroenterology center- Bulle, Gastroenterology, Bulle, Switzerland;(3)Bern University Hospital., Clinic for Visceral Surgery and Medicine-, Bern, Switzerland;(4)Lausanne University Hospital- CHUV, Gastroenterology, Lausanne, Switzerland;
P163: Incidence and risk of hip replacement rate in patients with inflammatory bowel disease in Taiwan:ECCO'24Year: 2024
Authors: Lai, H.C.(1);Wu, Y.H.(2)*; Wang, C.P.(2);Huang, P.J.(2);Cheng, K.S.(2);Chou, J.W.(2);
(1)School of Chinese Medicine- China Medical University- Taiwan, Graduate Institute of Chinese Medicine, Taichung, Taiwan;(2)China Medical University Hospital- Taiwan, Center for Digestive Medicine- Department of Internal Medicine, Taichung, Taiwan;
P164: Early monitoring of ustekinumab concentration after induction is related to clinical remission in ulcerative colitis & Crohn`s disease - STOCUSTE studyECCO'24Year: 2024
Authors: Sabhan, H.(1)*;
(1)St: Görans hospital, Internal Medicine / Gastroenterology, Kista, Sweden;F Johansson3 F Bello4 C Wennerström5 O Forsberg5 A Borin6 S Almer7 C Höög8 C Söderman2 M Lördal M1 1 1 Division of Gastroenterology and Hepatology Department of Medicine Danderyd Hospital Danderyd Sweden 2 4 Gastroenterology Unit Medical Department S:t Göran’s Hospital Stockholm Sweden 3 2 Medical library at Danderyd Hospital Danderyd Sweden 4 3 Division of Gastroenterology Karolinska university hospital Stockholm Sweden 5 5 Janssen Cilag AB Stockholm Sweden 6 6 Department of Medicine South Hospital Stockholm Sweden 7 8 Department of Medicine Solna Karolinska Institutet Stockholm Sweden 8 7 Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden
P164: MRT-6160, a VAV1-directed molecular glue degrader, inhibits disease progression and inflammation in a T-cell transfer model of Colitis.ECCO'24Year: 2024
Authors: CartwrightPh.D, A.(1);Desai, F.(2);Nguyen, S.(3);Trouilloud, A.(2);Vora, S.(2);Gyger, L.(1);Roditi, L.(4);Lam, D.(5);Trenh, P.(6);Lucas, X.(4);Zlotosch, M.(5);Liardo, E.(7);Wible, D.(2);Oleinikovas, V.(4);Lamberto, I.(5);Demarco, B.(8);King, C.(3);Bonenfant, D.(9);Townson, S.(10);Wallace, O.(2);Krishnan, E.(11);De Beukelaer, S.(12)*;Janku, F.(11);McAllister, L.(7);Paterson, A.(2);Peluso, M.(2);
(1)Monte Rosa Therapeutics, Target and Discovery Biology, Basel, Switzerland;(2)Monte Rosa Therapeutics, Target and Discovery Biology, Boston, United States;(3)Monte Rosa Therapeutics, Nonclinical Development and Clinical Pharmacology, Boston, United States;(4)Monte Rosa Therapeutics, Data Sciences, Basel, Switzerland;(5)Monte Rosa Therapeutics, Automation and Screening, Boston, United States;(6)Monte Rosa Therapeutics, Structural Biology, Boston, United States;(7)Monte Rosa Therapeutics, Chemistry, Basel, Switzerland;(8)Monte Rosa Therapeutics, Discovery Technologies, Boston, United States;(9)Monte Rosa Therapeutics, Proteomics, Basel, Switzerland;(10)Monte Rosa Therapeutics, Biomolecular Sciences, Boston, United States;(11)Monte Rosa Therapeutics, Clinical Development, Boston, United States;(12)Monte Rosa Therapeutics, Clinical Development, Basel, Switzerland;
P165: Epidemiology and distinct features of inflammatory bowel disease in South Asia: a systematic reviewECCO'24Year: 2024
Authors: Shenoy, S.(1,2)*;Jena, A.(3);Levinson, C.(4);Sharma, V.(2,5);Deepak, P.(2,6);Aswani-Omprakash, T.(2);Sebastian, S.(2,7);Colombel, J.F.(8);Agrawal, M.(8,9);
(1)Mount Sinai Morningside Hospital, Department of Medicine, New York, United States;(2)South Asian IBD Alliance SAIA, South Asian IBD Alliance SAIA, New York, United States;(3)Institute of Medical Sciences and SUM Hospital, Department of Gastroenterology, Bhubaneshwar, India;(4)Icahn School of Medicine at Mount Sinai, Levy Library, New York, United States;(5)Post Graduate Institute of Medical Education and Research, Department of Gastroenterology, Chandigarh, India;(6)Washington University in St. Louis School of Medicine, IBD center- Division of Gastroenterology, St. Louis, United States;(7)Hull University Teaching Hospitals, IBD unit, Hull HU3 2JZ, United Kingdom;(8)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(9)Center for Molecular Prediction of Inflammatory Bowel Disease PREDICT- Aalborg University, Department of Clinical Medicine, Copenhagen, Denmark;
P165: Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling.ECCO'24Year: 2024
Authors: Atreya, R.(1)*;Abreu, M.T.(2);Krueger, J.G.(3);Eyerich, K.(4,5);Greving, C.(6);Hammaker, D.(6);Stoveken, B.(7);Hartman, J.(7);Leppard, K.(8);Sarabia, I.(6);Wertheimer, J.(8);Deming, J.(6);Kohler, K.(9);Li, H.(10);Freeman, T.(10);Hart, A.(10);Keyes, B.(11);Ritchlin, C.(12);McInnes, I.B.(13);Allez, M.(14);Fourie, A.(6);Sachen, K.(6);
(1)Erlangen University Hospital- Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany;(2)University of Miami, Leonard Miller School of Medicine, Miami FL, United States;(3)The Rockefeller University, Laboratory for Investigative Dermatology, New York- NY, United States;(4)University of Freiburg, Medical Center, Freiburg, Germany;(5)Karolinska Institute, Department of Medicine – Division of Dermatology and Venereology, Stockholm, Sweden;(6)Janssen Research & Development LLC, Immunology, San Diego CA, United States;(7)Janssen Research & Development LLC, Computational Biology, Spring House PA, United States;(8)Janssen Research & Development LLC, Immunology, Spring House PA, United States;(9)Janssen Research & Development LLC, Statistics & Decision Science, San Diego CA, United States;(10)Janssen Research & Development LLC, Translational Science, Spring House PA, United States;(11)Janssen Research & Development LLC, Translational Science, San Deigo CA, United States;(12)University of Rochester, Department of Medicine - Allergy/Immunology and Rheumatology, Rochester NY, United States;(13)University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom;(14)Hôpital Saint-Louis, Université Paris Cité, Paris, France;
P166: Optimizing PD-1 agonist signaling with membrane proximal binding of rosnilimab, a clinical stage PD-1 agonist IgG1 antibodyECCO'24Year: 2024
Authors: Parmley, S.(1);Szlyk, B.(1);Frank, R.T.(1);Hsu, M.(1);Brodsky, P.(1);Sibley, C.(2);Lizzul, P.(2);Dahl, M.(1)*;
(1)AnaptysBio- Inc, Research, San Diego, United States;(2)AnaptysBio- Inc, Clinical, San Diego, United States;
P166: Thiopurines and Risk of Cancer in Patients with Inflammatory Bowel Disease -A Danish Nationwide Cohort study 1996-2018ECCO'24Year: 2024
Authors: Wewer, M.D.(1,2)*;Letnar, G.(3);Andersen, K.K.(3);Malham, M.(2,4,5);Wewer, V.(2,4,6);Seidelin, J.B.(6,7);Bendtsen, F.(1,2,6);Burisch, J.(1,2);
(1)Hvidovre Hospital- University of Copenhagen, Gastro Unit- Medical Division, Hvidovre, Denmark;(2)Hvidovre Hospital- University of Copenhagen, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(3)Omicron ApS, Omicron ApS, Copenhagen, Denmark;(4)Hvidovre Hospital- University of Copenhagen, The Department of Paediatrics and Adolescent Medicine, Hvidovre, Denmark;(5)Boston University School of Public Health- Boston, Departments of Epidemiology and Global Health, Boston, United States;(6)University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark;(7)Herlev Hospital- University of Copenhagen, Department of Gastroenterology, Herlev, Denmark;
P167: Inflammatory Bowel Disease: a phenome-wide pre- and post-diagnostic association studyECCO'24Year: 2024
Authors: Ebert, A.(1);ElmahdiMBBS- PhD, R.(1,2)*;Poulsen, G.(1);Bøgsted, M.(1);Verstockt, B.(3,4);Lees, C.(5);Jess, T.(1,6);
(1)National Center of Excellence for the Molecular Prediction of IBD, Clinical Medicine- Aalborg University, Copenhagen, Denmark;(2)Aalborg University Hosptial, Gastroenterology and Hepatology, Aalborg, Denmark;(3)University Hosptials Leuven, Gastroloenterology and Hepatology, Leuven, Belgium;(4)KU Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(5)Centre for Genomic and Experimental Medicine, Institue of Genetics and Cancer- University of Edinburgh, Edinburgh, United Kingdom;(6)Aalborg University Hospital, Gastroenterology and Hepatology, Aalborg, Denmark;
P168: Specialized pro-resolving lipid mediator Resolvin D1 and omega 6 dihomo-γ-linolenic acid are unable to solve inflammation in the creeping fat of patients with severe postoperative recurrence in Crohn@E@s disease.ECCO'24Year: 2024
Authors: Suau, R.(1)*;Pardina, E.(2);Clua, L.(1);Cordobilla, B.(2);Zabana, Y.(3,4);Calafat, M.(1,4,5);Carmona-Maurici, J.(2);Guasch, M.(6);Lorén, V.(1);Ricart-Jané, D.(2);Viñas-Calaf, A.(2);Fluvià, L.(7);Aguilar, R.(8);Mañosa, M.(1,4,5);Dobaño, C.(8,9);Hernández, J.M.(7);López-Tejero, M.D.(2);Domingo, J.C.(2);Domènech, E.(1);Serena, C.(10);Manyé, J.(1,4);
(1)Germans Trias i Pujol Research Institute IGTP, IBD Research Group, Badalona, Spain;(2)University of Barcelona, Biochemistry and Molecular Biomedicine Department, Barcelona, Spain;(3)MútuaTerrassa University Hospital, Digestive System Service, Terrassa, Spain;(4)Centro de Investigación Biomédica en Red CIBER, Enfermedades Hepáticas y Digestivas CIBEREHD, Madrid, Spain;(5)University Hospital Germans Trias i Pujol HUGTP, Digestive Tract Service, Badalona, Spain;(6)Hospital Parc Sanitari Sant Joan de Déu, Departament de Cirurgia, Sant Boi de Llobregat, Spain;(7)IGTP, Proteomics and Metabolomics Unit, Badalona, Spain;(8)Institute for Global Health ISGLOBAL- University of Barcelona- Hospital Clínic, Malaria Immunology Research Group, Barcelona, Spain;(9)CIBER, CIBER Enfermedades Infecciosas, Barcelona, Spain;(10)Institut d@E@Investigació Sanitària Pere Virgili IISPV, Inflammatory Bowel Disease IBODI Research Group, Tarragona, Spain;
P169: Circulating eNAMPT predicts anti-TNF response in IBD patients: possible place in therapy of anti-eNAMPT antibodyECCO'24Year: 2024
Authors: TravelliPh.D, C.(1)*;Cascetta, G.(2);colombo, G.(3);Alessi, A.(2);Caputo, E.(2);Lenti, M.V.(4);Pasini, A.(4);Porta , C.(3);Ribaldone, D.(5);Pastorelli, L.(6);Di Sabatino, A.(7);Genazzani, A.(3);Caviglia, G.P.(8);Stocco, G.(9);
(1)Università degli Studi di Pavia, Dipartimento di Scienze del Farmaco, pavia, Italy;(2)Università di Pavia, Scienze del Farmaco, Pavia, Italy;(3)Università del Piemonte Orientale, scienze farmaceutiche, Novara, Italy;(4)Università di Pavia, Medicina Interna, Pavia, Italy;(5)Università di Torino, Surgical Sciences, Torino, Italy;(6)IRCCS Policlinico San Donato, San Donato, Milano, Italy;(7)IRCCS San Matteo, Medicina Interna, Pavia, Italy;(8)Università di Torino, Scienze Mediche, Torino, Italy;(9)Università di Trieste, Life Sciences, Trieste, Italy;
P169: Multimorbidity and Disease Trajectories in Patients with INFLAMMATORY BOWEL DISEASES: Insights from Observational and Genetic AnalysesECCO'24Year: 2024
Authors: Jiang, F.(1)*;Zhao, J.(1);Chen, J.(1);Wang, L.(2);Yuan, S.(3);Kalla, R.(4);Wellens, J.(5);Nowak, J.(6);Larrson, S.(3);Ludvigsson, J.(7);Satsangi, J.(8);Theodoratou, E.(2);Li, X.(1);
(1)Zhejiang University School of Medicine, Department of Big Data in Health Science School of Public Health and The Second Affiliated Hospital, Hangzhou, China;(2)University of Edinburgh, Centre for Population Health Sciences- Usher Institute, Edinburgh, United Kingdom;(3)Karolinska Institutet, Unit of Cardiovascular and Nutritional Epidemiology- Institute of Environmental Medicine, Stockholm, Sweden;(4)University of Edinburgh, Department of Gastroenterology- Royal Infirmary of Edinburgh, Edinburgh, United Kingdom;(5)Translational Research Center for Gastrointestinal Disorders TARGID, KU Leuven Department of Chronic Diseases and Metabolism, Leuven, Belgium;(6)Poznan University of Medical Sciences, Department of Paediatric Gastroenterology and Metabolic Diseases, Poznan, Poland;(7)Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden;(8)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Medicine- Experimental Medicine Division, Oxford, United Kingdom;
P170: SLC7A5 promotes the progression of Ulcerative Colitis by regulating amino acid transport and intestinal epithelial autophagyECCO'24Year: 2024
Authors: Shi, Y.(1)*;Wang, F.(1);Hou, L.(1);Zhou, H.(1);Wu, T.(1);Li, R.(1);Li, X.(1);Liu, X.(1);Fan, Z.(1);Zhang, T.(1);Da, Y.(1);Liang, J.(1);
(1)Fourth Military Medical University, Xijing Hospital of Digestive Diseases, Xi@E@an, China;
P171: Rescuing Intestinal Stem Cells via TMEM219 inhibition promotes mucosal healing in Crohn’s diseaseECCO'24Year: 2024
Authors: D@E@Addio , F.(1);Canducci , F.(2)*;Marin , V.(2);Assi , E.(3);Maestroni , A.(4);Nardini , M.(4);Petrazzuolo , A.(4);Loretelli , C.(5);Usuelli , V.(4);Moufida , B.N.(4);Sampietro , G.(6);Ardizzone , S.(7);Fiorina , P.(8);
(1)University of Milan, Pediatric Clinical Research Center - Biomedical and Clinical Science, Milan, Italy;(2)Enthera, Enthera, Milan, Italy;(3)University of Milan, Pediatric Clinical Research Center Invernizzi- Biomedical and Clinical Science, Milan, Italy;(4)University of Milan, Pediatric Clinical Research Center Invernizzi- Biomedical and Clinical Sciences, Milan, Italy;(5)University of Milan, Pediatric Clinical Research Center- Biomedical and Clinical Sciences, Milan, Italy;(6)Rho Memorial Hospital- ASST Rhodense, Division of General and HBP Surgery, Rho, Italy;(7)ASST Fatebenefratelli-Sacco, Gastroenterology Division, Milan, Italy;(8)Pediatric Clinical and Research Center, Biomedical and Clinical Sciences, Milan, Italy;
P172: Spatial Transcriptomics Characterization of S1P Pathway Genes in Ulcerative Colitis and Crohn’s Disease Colon TissuesECCO'24Year: 2024
Authors: Zhang, J.(1)*;Maddux, R.(1);Petersen, A.(2);Mehandru, S.(3);Stauffer, W.(4);Baichwal, V.(4);Harris, S.(1);
(1)Bristol Myers Squibb, Translational Medicine, Princeton NJ, United States;(2)Bristol Myers Squibb, Clinical Development Gastroenterology, Princeton NJ, United States;(3)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology- Susan and Leonard Feinstein Inflammatory Bowel Disease Center, New York, United States;(4)Canopy Biosciences, Canopy Biosciences, Hayward CA, United States;
P173: Characterization of the gut microbiota and the colonic immune response in acute severe ulcerative colitis : the multi-omics ITAC project.ECCO'24Year: 2024
Authors: Riviere, P.(1,2,3)*;Dallmann-Sauer, M.(3);Enaud, R.(4);Bessissow, T.(5);Treton, X.(6);Uzzan, M.(7);Poullenot, F.(8);Zerbib, F.(8);Laharie, D.(8);Schurr, E.(9,10);
(1)Bordeaux University Hospital, Gastroenterology unit, Pessac, France;(2)McGill University, Microbiology and Immunology Department, Montréal, Canada;(3)Research Institute of the McGill University Health Centre, Program in Infectious Diseases and Immunity in Global Health, Montréal, Canada;(4)Bordeaux University Hospitals, CRCM Pediatrique, Bordeaux, France;(5)McGill University Health Centre, Division of Gastroenterology and hepatology, Montréal, Canada;(6)Groupe Hospitalier Privé Ambroise Paré-Hartmann, Paris IBD Center, Neuilly/Seine, France;(7)Paris Est Créteil University UPEC- Assistance Publique-Hôpitaux de Paris AP-HP- Henri Mondor Hospital, Gastroenterology department- Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Créteil, France;(8)Bordeaux University Hospitals, Gastroenterology department, Bordeaux, France;(9)Research Institute of McGill University Health Centre, Program in Infectious Diseases and Immunity in Global Health, Montréal, Canada;(10)McGill University, Mirobiology and Immunology department, Montréal, Canada;
